Microbiome, Parkinson’s Disease and Molecular Mimicry
AbstractParkinson’s Disease (PD) is typically classified as a neurodegenerative disease affecting the motor system. Recent evidence, however, has uncovered the presence of Lewy bodies in locations outside the CNS, in direct contact with the external environment, including the olfactory bulbs and the enteric nervous system. This, combined with the ability of alpha-synuclein (αS) to propagate in a prion-like manner, has supported the hypothesis that the resident microbial community, commonly referred to as microbiota, might play a causative role in the development of PD. In this article, we will be reviewing current knowledge on the importance of the microbiota in PD pathology, concentrating our investigation on mechanisms of microbiota-host interactions that might become harmful and favor the onset of PD. Such processes, which include the secretion of bacterial amyloid proteins or other metabolites, may influence the aggregation propensity of αS directly or indirectly, for example by favoring a pro-inflammatory environment in the gut. Thus, while the development of PD has not yet being associated with a unique microbial species, more data will be necessary to examine potential harmful interactions between the microbiota and the host, and to understand their relevance in PD pathogenesis. View Full-Text
Share & Cite This Article
Miraglia, F.; Colla, E. Microbiome, Parkinson’s Disease and Molecular Mimicry. Cells 2019, 8, 222.
Miraglia F, Colla E. Microbiome, Parkinson’s Disease and Molecular Mimicry. Cells. 2019; 8(3):222.Chicago/Turabian Style
Miraglia, Fabiana; Colla, Emanuela. 2019. "Microbiome, Parkinson’s Disease and Molecular Mimicry." Cells 8, no. 3: 222.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.